ZWJ Investment Counsel Inc. Buys 1,511 Shares of Johnson & Johnson $JNJ

ZWJ Investment Counsel Inc. grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 213,219 shares of the company’s stock after buying an additional 1,511 shares during the quarter. ZWJ Investment Counsel Inc.’s holdings in Johnson & Johnson were worth $32,569,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of JNJ. Elios Financial Group Inc. raised its holdings in Johnson & Johnson by 1.5% in the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock valued at $746,000 after buying an additional 66 shares during the last quarter. Atlantic Family Wealth LLC raised its stake in shares of Johnson & Johnson by 4.4% during the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock valued at $266,000 after acquiring an additional 67 shares during the last quarter. MBA Advisors LLC lifted its holdings in shares of Johnson & Johnson by 1.2% during the first quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock worth $921,000 after purchasing an additional 68 shares during the period. Nabity Jensen Investment Management Inc grew its stake in shares of Johnson & Johnson by 1.5% in the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company’s stock worth $767,000 after purchasing an additional 69 shares during the last quarter. Finally, Jackson Grant Investment Advisers Inc. increased its holdings in Johnson & Johnson by 0.5% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 12,970 shares of the company’s stock valued at $2,151,000 after purchasing an additional 69 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Up 1.4%

Shares of NYSE JNJ opened at $188.51 on Monday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $189.78. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm has a market cap of $453.98 billion, a PE ratio of 20.16, a P/E/G ratio of 2.40 and a beta of 0.40. The company’s fifty day simple moving average is $176.18 and its 200 day simple moving average is $162.83.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. During the same quarter in the prior year, the firm earned $2.82 EPS. The business’s revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Analyst Ratings Changes

A number of equities research analysts have commented on JNJ shares. Bank of America upped their price target on Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a research report on Friday. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Barclays upped their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Finally, UBS Group set a $198.00 target price on shares of Johnson & Johnson in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $188.88.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.